Citations

Clear

3030 citation(s) found for "Susan, M".

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Wang, Victoria , Hanson, Curtis A. , Tschumper, Renee C. , Lesnick, Connie , Braggio, Esteban , Paietta, Elisabeth , Leis, José F., Zhang, Cong Christine, Coutré, Steven , Cashen, Amanda F. , Mato, Anthony R. , Singh, Avina K., Mullane, Michael P., Stone, Richard M. , Litzow, Mark R. , Tallman, Martin S. , Shanafelt, Tait D. , Lesnick, Connie E, Leis, Jose Francisco, Barr, Paul M , Erba, Harry Paul , Litzow, Mark R. , Kay, Neil E , Shanafelt, Tait D , Braggio, Esteban , O’Brien, Susan , Barrientos, Jacqueline C. , Barr, Paul M. , Kay, Neil E.

Mayo Clinic

Blood | August 18, 2021 | Volume: 138 | Issue: 26 | Pages: 2810-2827

10.1182/blood.2020010146 | PMID 34407545 Get It

Abstract E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL. We describe measurable residual disease (MRD) levels in E1912 over time and correlate them with clinical outcome. Undetectable MRD rates (<1 CLL cell per 104 leukocytes) were 29.1%, 30.3%, 23.4%, and 8.6% at 3, 12, 24, and 36 months for FCR, and significantly lower at 7.9%, 4.2%, and 3.7% at 12, 24, and 36 months for IR, respectively. Undetectable MRD at 3, 12, 24, and 36 months was associated with longer progression-free survival (PFS) in the FCR arm, with hazard ratios (MRD detectable/MRD undetectable) of 4.29 (95% confidence interval [CI], 1.89-9.71), 3.91 (95% CI, 1.39-11.03), 14.12 (95% CI, 1.78-111.73), and not estimable (no events among those with undetectable MRD), respectively. In the IR arm, patients with detectable MRD did not have significantly worse PFS compared with those in whom MRD was undetectable; however, PFS was longer in those with MRD levels <10−1 than in those with MRD levels above this threshold. Our observations provide additional support for the use of MRD as a surrogate end point for PFS in patients receiving FCR. In patients on indefinite ibrutinib-based therapy, PFS did not differ significantly by undetectable MRD status, whereas those with MRD <10−1 tended to have longer PFS, although continuation of ibrutinib would very likely be necessary to maintain treatment efficacy.
Use of Artificial Intelligence Tools Across Different Clinical Settings
Siontis, Konstantinos C. , Arghami, Arman , Weston, Susan A., Attia, Zachi I. , Crestanello, Juan A. , Friedman, Paul A. , Chamberlain, Alanna M. , Gersh, Bernard J. , Arghami, Arman , Attia, Zachi I , Crestanello, Juan A , Chamberlain, Alanna M , Gersh, Bernard J , Noseworthy, Peter A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | August 16, 2021 | Volume: 14 | Issue: 9 | Pages: No page available

10.1161/circoutcomes.121.008153 | PMID 34397260 Get It

Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Naidu, Srihari S. , Baron, Suzanne J. , Eng, Marvin H. , Sathanandam, Shyam , Zidar, David A., Feldman, Dmitriy N. , Ing, Frank F. , Latif, Faisal , Lim, Michael J. , Henry, Timothy D. , Dangas, George , Hermiller, James, Daggubati, Ramesh , Ang, Lawrence , Box, Lyndon C., Caputo, Ronald , Cohen, Mauricio G. , Coylewright, Megan , Duffy, Peter L. , Goldsweig, Andrew M. , Hagler, Donald J. , Hawkins, Beau M., Hijazi, Ziyad M. , Jayasuriya, Sasanka, Klein, Andrew , Kliger, Chad , Mahmud, Ehtisham , Messenger, John C. , Parikh, Sahil A. , Shishehbor, Mehdi H. , Yakubov, Steven J. , Alvarez‐Breckenridge, Jennifer, Baird, Colleen, Baker, David, Berry, Charles H., Bhattacharya, Manisha, Bilazarian, Seth, Bowen, Rosanne, Brounstein, Kevin, Cameron, Cole, Culbertson, Casey , Díaz, P, Emanuele, Susan, Evans, Erin, Fletcher, Rob, Fortune, Tina, Gaiha, Priya, Govender, Devi, Gutfinger, Dan , Haggstrom, Kurt, Herzog, Andrea, Hite, Denise, Kalich, Bethany , Kirkland, Ann, Kohler, Toni, Laurisden, Holly, Livolsi, Kevin, Lombardi, Lois, Marhenke, Kevin, Meikle, Joie, Moat, Neil, Popma, J.J., Rangwala, Novena , Simonton, Chuck, Stokes, J. W., Taber, Margaret , Tieché, Christopher, Venditto, John, Zinn, Laurie, Dangas, George , Daggubati, Ramesh , Shah, Binita , Ang, Lawrence , Cohen, Mauricio G , Goldsweig, Andrew M , Hagler, Donald J , Morray, Brian H , Parikh, Sahil A , Shishehbor, Mehdi H , Szerlip, Molly , Yakubov, Steven J , Grines, Cindy L , Baron, Suzanne J , Rao, Sunil V. , Shah, Binita , Aronow, Herbert D. , Banerjee, Subhash , Justino, Henri , Li, Jun , Morray, Brian H. , Parikh, Sahil A. , Reilly, John P. , Secemsky, Eric A. , Grines, Cindy L. , Baker, David, Berry, Charles, Cavalcante, Rafael , Diaz, Pedro, Kohler, Toni, Lowe, Sarah, Mueller, Megan, Patarca, Roberto , Stokes, Jerry, West, Nick E.J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 16, 2021 | Volume: 98 | Issue: 5 | Pages: 904-913

10.1002/ccd.29898 | PMID 34398509 Get It

AbstractThe Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high‐level field‐wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
High Return to Play Rate and Reduced Career Longevity Following Surgical Management of Athletic Pubalgia in National Basketball Association Players
Castle, Joshua , Kessler, Adam , Wager, Susan , Khalil, Lafi S. , Okoroha, Kelechi R. , Mehran, Nima , Abbas, Muhammad J.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | August 10, 2021 | Volume: 3 | Issue: 5 | Pages: No page available

10.1016/j.asmr.2021.07.001 | PMID 34712974 Get It

Purpose To assess the effects of surgical treatment of athletic pubalgia (AP) on game use and performance metrics in National Basketball Association (NBA) players. Methods A retrospective review of all NBA players who underwent surgical management for AP from 1996 to 2018 was performed. A matched control group was created for comparison. The index period was defined as the entire NBA season in which surgery occurred, including the corresponding offseason. Player demographics, use (games played, games started, and minutes per game) and performance (player efficiency rating) metrics were collected for all players. Statistical analysis was performed to compare data before and after return to play. Results Thirty players with a history of surgical management for AP were included in the final analysis. Following surgery for AP, NBA players were found to have a return to play (RTP) rate of 90.91% (30/33). The average RTP following surgery was 4.73 ± 2.62 months. Compared with control athletes, athletes in the AP group played significantly fewer seasons postinjury (4.17 ± 2.70 vs 5.49 ± 3.04 seasons, respectively; P = .02). During the first year following RTP, NBA players experienced significant reductions in game use and performance, both when compared with the year prior and matched control athletes ( P < .05). At 3‐year follow‐up, players continued to demonstrate significant reductions in game use (minutes per game, P < .05) but not performance. Conclusions Following surgical treatment of AP, NBA players demonstrated a high RTP rate, but shortened career. A short‐term reduction in game use and performance metrics was found the year of return following surgery. However, 3‐year follow‐up performance metrics normalized when compared with healthy controls. Study Design Level III; retrospective case‐control study.
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report
Benjamin, Emelia J. , Al‐Khatib, Sana M. , Desvigne‐Nickens, Patrice , Alonso, Álvaro , Djoussé, Luc , Forman, Daniel E. , Gillis, Anne M. , Hendriks, Jeroen , Hills, Mellanie True , Kirchhof, Paulus , Marcus, Gregory M. , Murray, Katherine T. , Parkash, Ratika , Redline, Susan , Rienstra, Michiel , Wang, Paul J. , Cooper, Lawton S. , Go, Alan S. , Alonso, Alvaro , Kirchhof, Paulus , True Hills, Mellanie , Rienstra, Michiel , Benjamin, Emelia J , Hendriks, Jeroen M , Marcus, Gregory M , Forman, Daniel Edward , Link, Mark S. , Mehra, Reena , Piña, Ileana L. , Sanders, Prashanthan , Somers, Virend K. , Wagoner, David R. Van , Al-Khatib, Sana M.

Mayo Clinic

Journal of the American Heart Association | August 5, 2021 | Volume: 10 | Issue: 16 | Pages: No page available

10.1161/jaha.121.021566 | PMID 34351783 Get It

There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF‐related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced‐based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF‐related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team‐based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
NCCN Guidelines® Insights: Palliative Care, Version 2.2021
Dans, Maria, Kutner, Jean S. , Agarwal, Rajiv , Baker, Justin N. , Bauman, Jessica R. , Carey, Elise C. , Dalal, Shalini , Doberman, Danielle J. , Fecher, Leslie A. , Kapo, Jennifer, Lee, Richard T. , McCammon, Susan , Mitchell, William M. , Ogunseitan, Adeboye, Portman, Diane , Ramchandran, Kavitha , Sutton, Linda , Teply, Melissa , Terauchi, Stephanie , Walling, Anne M. , Zachariah, Finly , Bergman, Mary Anne, Ogba, Ndiya , Campbell, Mallory, Agarwal, Rajiv , Ramchandran, Kavitha J , Beck, Anna Catherine , Campbell, Toby C. , Case, Amy Allen , Epstein, Andrew S , Jones, Joshua , Loggers, Elizabeth T , Mitchell, William, Temel, Jennifer S. , Thomas, Jane deLima

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 2, 2021 | Volume: 19 | Issue: 7 | Pages: 780-788

10.6004/jnccn.2021.0033 | PMID 34340208 Get It

Palliative care has evolved to be an integral part of comprehensive cancer care with the goal of early intervention to improve quality of life and patient outcomes. The NCCN Guidelines for Palliative Care provide recommendations to help the primary oncology team promote the best quality of life possible throughout the illness trajectory for each patient with cancer. The NCCN Palliative Care Panel meets annually to evaluate and update recommendations based on panel members’ clinical expertise and emerging scientific data. These NCCN Guidelines Insights summarize the panel’s recent discussions and highlights updates on the importance of fostering adaptive coping strategies for patients and families, and on the role of pharmacologic and nonpharmacologic interventions to optimize symptom management.
TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
Redondo, María J. , Warnock, Megan, Libman, Ingrid , Bocchino, Laura E., Cuthbertson, David , Geyer, Susan, Pugliese, Alberto , Steck, Andrea K. , Becker, Dorothy J., Sosenko, Jay M. , Bacha, Fida , Group, the Type 1 Diabetes TrialNet Study, Evans‐Molina, Carmella , Group, the Type 1 Diabetes TrialNet Study

Mayo Clinic

Diabetes Care | July 29, 2021 | Volume: 44 | Issue: 9 | Pages: 2039-2044

10.2337/dc21-0531 | PMID 34326068 Get It

OBJECTIVE We aimed to test whether type 2 diabetes (T2D)–associated TCF7L2 genetic variants affect insulin sensitivity or secretion in autoantibody-positive relatives at risk for type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS We studied autoantibody-positive TrialNet Pathway to Prevention study participants (N = 1,061) (mean age 16.3 years) with TCF7L2 single nucleotide polymorphism (SNP) information and baseline oral glucose tolerance test (OGTT) to calculate indices of insulin sensitivity and secretion. With Bonferroni correction for multiple comparisons, P values &lt; 0.0086 were considered statistically significant. RESULTS None, one, and two T2D-linked TCF7L2 alleles were present in 48.1%, 43.9%, and 8.0% of the participants, respectively. Insulin sensitivity (as reflected by 1/fasting insulin [1/IF]) decreased with increasing BMI z score and was lower in Hispanics. Insulin secretion (as measured by 30-min C-peptide index) positively correlated with age and BMI z score. Oral disposition index was negatively correlated with age, BMI z score, and Hispanic ethnicity. None of the indices were associated with TCF7L2 SNPs. In multivariable analysis models with age, BMI z score, ethnicity, sex, and TCF7L2 alleles as independent variables, C-peptide index increased with age, while BMI z score was associated with higher insulin secretion (C-peptide index), lower insulin sensitivity (1/IF), and lower disposition index; there was no significant effect of TCF7L2 SNPs on any of these indices. When restricting the analyses to participants with a normal OGTT (n = 743; 70%), the results were similar. CONCLUSIONS In nondiabetic autoantibody-positive individuals, TCF7L2 SNPs were not related to insulin sensitivity or secretion indices after accounting for BMI z score, age, sex, and ethnicity.
Addressing a Missing Link in Emergency Preparedness: New Insights on the Ethics of Care in Contingency Conditions from the Minnesota COVID Ethics Collaborative
Wu, Joel T., DeBruin, Debra, Wolf, Susan M. , Klemond, Thomas, DeMartino, Erin S.

Mayo Clinic

The American Journal of Bioethics | July 27, 2021 | Volume: 21 | Issue: 8 | Pages: 17-19

10.1080/15265161.2021.1939809 | PMID 34313570 Get It

Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Bhindi, Bimal , Bearrick, Elizabeth , Cheville, John C. , Lohse, Christine M. , Mason, Ross , Shah, Paras , Harrington, Susan M. , Boorjian, Stephen A. , Thompson, R. Houston, Leibovich, Bradley C. , Zhang, Henan , Dong, Haidong

Mayo Clinic

Kidney Cancer | July 27, 2021 | Volume: 5 | Issue: 3 | Pages: 129-135

10.3233/kca-210116 Get It

BACKGROUND: Bim (BCL-2-interacting mediator of cell death) is a downstream pro-apoptotic signaling molecule activated by the PD-1 pathway. OBJECTIVE: We sought to determine if Bim expression in peritumoral T-lymphocytes (PTLs) is associated with survival in patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: Immunohistochemistry staining for Bim was performed on paraffin-embedded tumor tissue blocks from patients with metastatic ccRCC who underwent nephrectomy between 1990-2004. Associations of Bim expression with cancer-specific survival (CSS) and overall survival (OS) from date of metastasis were evaluated using multivariable Cox regression models, adjusting for age, sex, and metastases-score. RESULTS: 525 patients with metastatic ccRCC, of whom 169 (32%) had metastases at time of nephrectomy were studied. After multivariable adjustment, high Bim expression remained associated with worse CSS (HR = 1.31; 95% CI 1.07–1.59; p = 0.008) and OS (HR = 1.28; 95% CI 1.06–1.55; p = 0.01). The interaction between Bim and PD-L1 was not statistically significant for CSS ( p = 0.68) or OS ( p = 0.57), suggesting that the associations between Bim and survival outcomes were not significantly different based on tumor PD-L1 expression. CONCLUSION: High Bim expression in PTLs at nephrectomy is prognostic of worse CSS and OS in patients with metastatic ccRCC, irrespective of tumor PD-L1 expression. The role of earlier PD-1/PD-L1-directed therapy warrants evaluation in these patients.
Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores
Barnes, Daniel R. , Silvestri, Valentina , Leslie, Goska , McGuffog, Lesley, Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A. , Ahmed, Munaza, Aittomäki, Kristiina, Andrulis, Irene L. , Arason, Aðalgeir , Azzollini, Jacopo , Barkardóttir, Rósa B. , Barrowdale, Daniel , Belotti, Muriel, Berthet, Pascaline, Boonen, Susanne E. , Borg, Åke , Brady, Angela F., Brewer, Carole, Brunet, Joan , Bucalo, Agostino, Caldés, Trinidad , Cassingham, Hayley , Christensen, Lise Lotte , Cini, Giulia , Claes, Kathleen , Collaborators, GEMO Study, Collaborators, EMBRACE, Cortesi, Laura , Damante, Giuseppe , Darder, Esther , Davidson, Rosemarie, Leeneer, Kim De , Putter, Robin De , Valle, Jesús Del , Ding, Yuan Chun , Donaldson, Alan , Eason, Jacqueline , Eeles, Rosalind A. , Engel, Christoph , Evans, D. Gareth , Feliubadaló, Lídia , Frone, Megan N. , Frost, Debra, Gehrig, Andrea, Giraud, Sophie , Glendon, Gord , Goldgar, David E. , Greene, Mark H. , Gregory, Helen , Groß, Eva, Hahnen, Eric, Hamann, Ute, Hansen, Thomas van Overeem , Hanson, Helen , Horváth, Judit , Investigators, KConFab, Investigators, HEBON, Izatt, Louise , James, Paul A. , Janavičius, Ramūnas , Jensen, Uffe Birk , Johannsson, Oskar T., John, Esther M. , Kramer, Gero , Kroeldrup, Lone , Kruse, Torben A. , Lautrup, Charlotte Kvist , López‐Fernández, Adrià , Mai, Phuong L, Manoukian, Siranoush , Mátrai, Zoltán , Matricardi, Laura , Mebirouk, Noura, Meindl, Alfons , Montagna, Marco , Monteiro, Álvaro N.A. , Morrison, Patrick J. , Muranen, Taru , Nathanson, Katherine L. , Niederacher, Dieter , Oláh, Edith , Olopade, Olufunmilayo I. , Pedersen, Inge Søkilde , Peissel, Bernard , Peterlongo, Paolo , Petersen, Annabeth Høgh , Pinto, Pedro, Porteous, Mary, Pottinger, Caroline , Pujana, Miquel Angel, Ramser, Juliane, Rantala, Johanna, Rogers, Mark T., Rønlund, Karina, Abajo, A.M. SÁnchez De, Shah, Payal D. , Sharif, Saba , Side, Lucy, Stadler, Zsofia, Steele, Linda , Sutter, Christian , Tan, Yen Y. , Teixeira, Manuel R. , Teulé, Àlex , Thull, Darcy L. , Trainer, Alison H., Tripathi, Vishakha , Valentini, Virginia , Viel, Alessandra , Walker, Lisa, Wang‐Gohrke, Shan , Wappenschmidt, Barbara , Whaite, Anna , Offit, Kenneth, Thomassen, Mads , Schmutzler, Rita K., Simard, Jacques , Easton, Douglas F. , Chenevix‐Trench, Georgia , Antoniou, Antonis C. , Pujana, Miguel Ángel , Dennis, Joe , Yang, Xin , Adlard, Julian , Agnarsson, Bjarni A , Andrulis, Irene L , Arason, Adalgeir , Arnold, Norbert , Auber, Bernd , Azzollini, Jacopo , Barkardottir, Rosa B , Barrowdale, Daniel , Benitez, Javier , Boonen, Susanne E , Bozsik, Aniko , Brennan, Paul , Brunet, Joan , Bucalo, Agostino , Caligo, Maria A , Campbell, Ian G , Cassingham, Hayley , Cini, Giulia , Claes, Kathleen B M , Coppa, Anna , Cortesi, Laura , Darder, Esther , de la Hoya, Miguel , de Putter, Robin , Del Valle, Jesús , Domchek, Susan M , Donaldson, Alan , Eason, Jacqueline , Engel, Christoph , Fostira, Florentia , Frone, Megan , Glendon, Gord , Godwin, Andrew K. , Greene, Mark H , Hahnen, Eric , Hanson, Helen , Izatt, Louise , Izquierdo, Angel , James, Paul , John, Esther M , Kroeldrup, Lone , Kruse, Torben A , Lazaro, Conxi , Lesueur, Fabienne , Matrai, Zoltan , Montagna, Marco , Monteiro, Alvaro N , Morrison, Patrick J , Muranen, Taru A , Nathanson, Katherine L , Neuhausen, Susan L. , Nevanlinna, H , Nguyen-Dumont, Tu , Niederacher, Dieter , Palli, Domenico , Parsons, Michael T , Perez-Segura, Pedro , Peterlongo, Paolo , Pinto, Pedro , Pottinger, Caroline , Radice, Paolo , Robson, Mark , Rump, Andreas , Sharif, Saba , Steele, Linda , Stoppa-Lyonnet, Dominique , Teixeira, Manuel R , Thull, Darcy L , Tischkowitz, Marc D. , Toland, Amanda Ewart , Tommasi, Stefania , Toss, Angela , Tripathi, Vishakha , Valentini, Virginia , van Asperen, Christi J , Venturelli, Marta , Viel, Alessandra , Joseph, Vijai , Whaite, Anna , Simard, Jacques , Easton, Doug , Chenevix-Trench, Georgia , Ottini, Laura , Barnes, Daniel R , Leslie, Goska , Pujana, Miquel Angel , Eeles, Rosalind A , Evans, D Gareth , Matricardi, Laura , Olopade, Olufunmilayo I , Silvestri, Valentina , De Leeneer, Kim , Feliubadaló, Lidia , Hansen, Thomas van Overeem , Manoukian, Siranoush , Arnold, Norbert , Auber, Bernd , Balmañà, Judith , Barwell, Julian , Benı́tez, Javier , Bozsik, Anikó , Brady, Angela F., Buys, Saundra S. , Caligo, Maria A. , Campbell, Ian , Collaborators, GEMO Study, Collaborators, EMBRACE, Cook, Jackie A , Hoya, Miguel de la , Dı́ez, Orland , Domchek, Susan M. , Gallagher, David James , Hentschel, Julia , Investigators, KConFab, Investigators, HEBON, Izquierdo, Á. , Lázaro, Conxi , Lesueur, Fabienne , Mai, Phuong L, Maxwell, Kara N. , Meindl, Alfons , Nevanlinna, Heli , Nguyen‐Dumont, Tú , Palli, Domenico , Parsons, Michael T. , Radice, Paolo , Robson, Mark E. , Rump, Andreas , Singer, Christian F. , Stoppa‐Lyonnet, Dominique , Asperen, Christi J. van , Vijai, Joseph , Zanna, Ines , Couch, Fergus J. , Ottini, Laura

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 26, 2021 | Volume: 114 | Issue: 1 | Pages: 109-122

10.1093/jnci/djab147 | PMID 34320204 Get It

AbstractBackgroundRecent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.Methods483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.ResultsPRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.ConclusionsPopulation-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.